依普利酮治疗高血压有效果吗？

(Inspra) is the first selective aldosterone receptor blocker approved for marketing. In recent years, more and more evidence has shown that other tissues, especially the heart, brain and blood vessels, can also independently synthesize aldosterone. Not only that, it can also directly affect blood pressure and damage the heart, brain, kidneys and other organs. Eplerenone has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction, has fewer adverse reactions and is well tolerated.

Is eplerenone effective in treating high blood pressure?

Subgroup analysis of the EPHESUS study showed that the effect of eplerenone on reducing overall mortality was more obvious in patients with hypertension. A comparative study on the efficacy and tolerability of 499 patients with grade 1 or 2 hypertension who were randomized to receive enalapril or eplerenone showed that at 6 months, enalapril was as effective as eplerenone (Inspra) in reducing systolic blood pressure (eplerenone decreased by 14.5 mmHg; enalapril decreased by 12.7 mmHg; P=0.199) and diastolic blood pressure (eplerenone decreased by 11.2 mmHg; enalapril decreased by 11.3 mm). Hg; P=0.910). After 12 months, the two groups were also similar (eplerenone -16.5/-13.3mmHg; enalapril -14.8/-14.1mmHg, P values ​​0.251 and 0.331 respectively).

About 2/3 of the patients in each group achieved normal blood pressure at 6 months with the above single treatment. In the eplerenone group, the reduction in blood pressure was independent of renin levels, unlike enalapril. Both groups could reduce proteinuria above normal levels, but the eplerenone group was more significant (-61.5% vs -25.7%; P=0.01).

It can be seen that (Inspra) not only has a significant effect on the treatment of hypertension, but also plays a very good role in reducing proteinuria, making it a good choice for patients with hypertension.

Recommended related hot articles: /newsDetail/73005.html